Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anneliene H Jonker

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Neuromuscular Disorders : NMD|October 2, 2025
Applying the international rare disease research consortium (IRDiRC) N-of-1 therapy task force eligibility criteria for individualised therapies use case: Duchenne muscular dystrophyAnnemieke Aartsma-Rus, Anneliene H Jonker, Daniel O'Connor
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|March 29, 2017
Deciphering tissue morphodynamics using bioimage informaticsAlexandre C Dufour, Anneliene H Jonker, Jean-Christophe Olivo-Marin
The Lancet. Global Health|September 20, 2024
Access in the rare diseases landscapeAnneliene H Jonker, Maria Cavaller-Bellaubi, Yukiko Nishimura, et al.
European Journal of Medical Genetics|October 7, 2024
Lessons learned from the RE(ACT) conference on medical devices for rare diseasesAnneliene H Jonker, Tim Buckinx, Lucia Pannese, et al.
Nature Reviews. Drug Discovery|December 16, 2024
IRDiRC perspectives on the application of digital biomarkers in therapeutic development for rare diseasesRajesh Krishna, Anneliene H Jonker, Thomas Morel, et al.
Drug Discovery Today|December 4, 2025
Non-oncology orphan drug development: Productivity and probability of successSamantha Parker, Jida El Hajjar, Anneliene H Jonker, et al.
Nature Reviews. Drug Discovery|January 26, 2022
Research on rare diseases: ten years of progress and challenges at IRDiRCLucia Monaco, Galliano Zanello, Gareth Baynam, et al.
European Journal of Human Genetics : EJHG|October 27, 2016
'IRDiRC Recognized Resources': a new mechanism to support scientists to conduct efficient, high-quality research for rare diseasesHanns Lochmüller, Yann Le Cam, Anneliene H Jonker, et al.
European Journal of Human Genetics : EJHG|November 22, 2017
The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impactHanns Lochmüller, Josep Torrent I Farnell, Yann Le Cam, et al.
Clinical and Translational Science|August 11, 2017
Progress in Rare Diseases Research 2010-2016: An IRDiRC PerspectiveHugh J S Dawkins, Ruxandra Draghia-Akli, Paul Lasko, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Neuromuscular Disorders : NMD|October 2, 2025
Applying the international rare disease research consortium (IRDiRC) N-of-1 therapy task force eligibility criteria for individualised therapies use case: Duchenne muscular dystrophyAnnemieke Aartsma-Rus, Anneliene H Jonker, Daniel O'Connor
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|March 29, 2017
Deciphering tissue morphodynamics using bioimage informaticsAlexandre C Dufour, Anneliene H Jonker, Jean-Christophe Olivo-Marin
The Lancet. Global Health|September 20, 2024
Access in the rare diseases landscapeAnneliene H Jonker, Maria Cavaller-Bellaubi, Yukiko Nishimura, et al.
European Journal of Medical Genetics|October 7, 2024
Lessons learned from the RE(ACT) conference on medical devices for rare diseasesAnneliene H Jonker, Tim Buckinx, Lucia Pannese, et al.
Nature Reviews. Drug Discovery|December 16, 2024
IRDiRC perspectives on the application of digital biomarkers in therapeutic development for rare diseasesRajesh Krishna, Anneliene H Jonker, Thomas Morel, et al.
Drug Discovery Today|December 4, 2025
Non-oncology orphan drug development: Productivity and probability of successSamantha Parker, Jida El Hajjar, Anneliene H Jonker, et al.
Nature Reviews. Drug Discovery|January 26, 2022
Research on rare diseases: ten years of progress and challenges at IRDiRCLucia Monaco, Galliano Zanello, Gareth Baynam, et al.
European Journal of Human Genetics : EJHG|October 27, 2016
'IRDiRC Recognized Resources': a new mechanism to support scientists to conduct efficient, high-quality research for rare diseasesHanns Lochmüller, Yann Le Cam, Anneliene H Jonker, et al.
European Journal of Human Genetics : EJHG|November 22, 2017
The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impactHanns Lochmüller, Josep Torrent I Farnell, Yann Le Cam, et al.
Clinical and Translational Science|August 11, 2017
Progress in Rare Diseases Research 2010-2016: An IRDiRC PerspectiveHugh J S Dawkins, Ruxandra Draghia-Akli, Paul Lasko, et al.
Pageof 2